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Background: End-stage chronic obstructive pulmonary disease has tradi-
tionally been treated with lung transplantation. For 2 years, our lung
transplantation program has placed patients with appropriate criteria for
lung transplantation and volume reduction into a prospective management
algorithm. These patients are offered the lung volume reduction option as
a “bridge” to “extend” the eventual time to transplantation. We examine
the results of this pilot program. Methods: From October 11, 1993, to April
17, 1997, 31 patients were evaluated for lung transplantation who also had
physiologic criteria for volume reduction (forced expiratory volume in 1
second <2 25%; residual volume > 200%; significant ventilation/perfusion
heterogeneity). All patients completed 6 weeks of pulmonary rehabilitation
and then had baseline pulmonary function and 6-minute walk tests. These
patients were then offered volume reduction as a “bridge” and were
simultaneously listed for transplantation. Postoperatively, these 31 pa-
tients were then divided into two groups: Those with satisfactory results at
4 to 6 months after volume reduction and those with unsatisfactory results.
Volume reduction was performed through a video thoracic approach in 87%
of the patients and bilateral median sternotomy in the remaining 13%. The
condition of the patients was monitored after the operation with repeated
pulmonary function tests and 6-minute walk tests at 3-month intervals.
Results: Twenty-four of 31 patients (77.4%) had primary success (at 4 to 6
months) results after lung volume reduction and 7 patients (22.6%) had
primary failure, including 1 patient who died in the perioperative period
(3.2%). Four patients (16.7%) from the primary success cohort had
significant deterioration in their pulmonary function during intermediate-
term follow-up and were then reconsidered for lung transplantation. Two of
them have subsequently undergone transplantation with good postopera-
tive pulmonary function results. Interestingly, three patients had a1-
antitrypsin deficiency; two had a poor outcome of lung volume reduction
and primary failure. Conclusions: Lung volume reduction in these patients
is safe. Seventy-seven percent of otherwise suitable candidates for lung
transplantation achieved initial good results from volume reduction and
were deactivated from the list (placed on status 7). Most patients entering
our prospective management algorithm have either significantly delayed or
completely avoided lung transplantation after volume reduction. Lung
volume reduction has substantially affected the practice, timing, and
selection of patients for lung transplantation. Our waiting list now has a
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reduced percentage of patients with a diagnosis of chronic obstructive
pulmonary disease compared with 3 years ago. Our experience suggests
that lung volume reduction may be limited as a “bridge” in a1-antitrypsin
deficiency. (J Thorac Cardiovasc Surg 1998;115:9-18)
The surgical treatment of chronic obstructive pul-monary disease (COPD) has historically been
quite a challenge. The initial attempt at lung volume
reduction (LVR) surgery for emphysema was made
by Brantigan and colleagues1 with little success.
However, giant bullous disease and other bullous
conditions have been treated surgically with success
for quite some time.2, 3 In the early 1980s, lung
transplantation was developed for end-stage COPD,
which initially included both heart-lung and double-
lung transplant procedures.4 The transplantation of
two lungs was thought to be necessary to alleviate
any severe ventilation/perfusion (V/Q) mismatch or
potential hyperinflationary mediastinal complica-
tions that were theoretically possible with single
lung transplantation (SLT).5 In 1989, Mal and asso-
ciates,6 as well as Calhoun and coworkers,7 reported
early clinical series of isolated SLT for COPD.
Bilateral sequential lung transplantation for
COPD has also been gaining favor more recent-
ly.8-10 Concurrent to the development of various
lung transplantation procedures designed to treat
end-stage COPD, other surgeons were investigating
the use of laser or other resection techniques in
patients with emphysema.11, 12 In 1995, Cooper and
colleagues13 presented a landmark series of patients
undergoing bilateral LVR for emphysema with me-
dian sternotomy with excellent short-term clinical
results. After this series was published, other sur-
geons reported good clinical results with both uni-
lateral and bilateral LVR by use of the newly
emerging video thoracic technology.14, 15
By 1994, it became clear to our lung transplanta-
tion team that some patients referred with end-stage
COPD were candidates for both LVR and lung
transplantation. The emergence of LVR as a treat-
ment modality for COPD and our encouraging
results in more than 150 patients over the past 3
years16 have allowed us to identify a subgroup of
patients with COPD who may benefit from LVR
either in lieu of lung transplantation or as a bridge
to transplantation. Our desire to develop alterna-
tives to lung transplantation has been further fueled
by the continued scarcity of available donor organs.
With these two effective treatment modalities avail-
able for end-stage COPD, our lung transplant pro-
gram developed a strategy for patients with appro-
priate criteria for both lung transplantation and
LVR and placed them into a prospective manage-
ment algorithm. Patients who were candidates for
both procedures were offered LVR as a preliminary
“bridge” to lung transplantation. It was completely
unclear to us, when designing this prospective algo-
rithm, whether LVR would be effective in these
patients with a low forced expiratory volume in 1
second (FEV1; #25%), especially in those patients
with an FEV1 , 19%, because scant patient data
were available on this particular cohort. Addition-
ally, it was unclear how many patients would obtain
sufficient benefit to allow the LVR procedure to
completely replace lung transplantation or whether
a successful LVR would simply act to “prolong” the
eventual time to transplantation. This report ana-
lyzes the results of our pilot program involving 31
patients who were prospectively placed in a surgical
management scheme consisting of (1) LVR, (2)
simultaneous listing for lung transplantation, and
(3) subsequent close follow-up at 4 to 6 months, at
which time a decision was made either to keep the
patient on the list (primary failure) or to place him
or her on status 7 (primary success).
Patients and methods
Source of referred patients. Four hundred fifty-six pa-
tients between October 30, 1991, and April 11, 1997, were
referred to the University of Pennsylvania Lung transplant
program for the evaluation of end-stage lung disease. Of
these patients, 225 (49.3%) had with end-stage COPD. This
diagnosis category includes end-stage emphysema and a1-
antitrypsin deficiency (A-1). Of these 225 evaluated patients,
35 (15.6%) were excluded for comorbid conditions. Twenty
(8.9%) patients did not fit the criteria for lung transplanta-
tion but were candidates for LVR. Beginning in October
1993, we recognized that some patients who would be good
candidates for lung transplantation would also be considered
appropriate candidates for LVR. Since October 1993, 31
(13.3%) patients were candidates for both LVR and lung
transplantation. This represents the core group of patients
studied in this series. The remaining 139 patients (61.8%)
were referred directly for lung transplantation and were not
considered for LVR.
Lung transplantation inclusion criteria. Lung trans-
plantation inclusion criteria for patients with end-stage
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COPD include (1) an FEV1 , 30% of predicted (by 1993
this was changed to an FEV1 , 25% predicted), (2) age ,
65, (3) no significant comorbidities and other organ
system dysfunction, (4) a 6-minute walk test (6MWT)
distance t 600 feet, (5) body weight not under or exceed-
ing 25% of predicted ideal range, (6) no history of
substance abuse, (7) no active or recent smoking, and (8)
adequate social support and stable psychosocial setting.
Inclusion criteria for LVR. During the early phases of
our program, the best indications for LVR were not
completely defined. As our experience grew, however, it
has become clear that inclusion criteria for LVR include
residual volume (RV) t than 200%, pulmonary artery
systolic pressure , 50 mm Hg, 6MWT t 600 feet, and a
quantitative V/Q scan that reveals significant “heteroge-
neity.” The most optimal V/Q scan for LVR reveals
bilateral apical flow distributions , 10% of the total.
Additionally, we excluded patients with a carbon dioxide
tension . 50 mm Hg. As in the lung transplant program,
anyone with active smoking was contraindicated for LVR.
Significant bronchospasm or an asthmatic component to
end-stage COPD was considered a contraindication to
operation. Identical weight restrictions as defined in the
lung transplant program exclusion criteria also applied to
LVR. All patients eligible for LVR were required to
undergo at least 6 weeks of formal pulmonary rehabilita-
tion. Repeat pulmonary function tests were then obtained
after pulmonary rehabilitation and before the LVR pro-
cedure.
Patient characteristics. Our pilot study group consists
of the 31 patients considered good candidates for either
procedure. A summary of the demographics for these 31
patients can be seen in Table I.
Decision making/pathway algorithm. Once patients
were considered candidates for both LVR and lung
transplantation, the following prospective algorithm was
followed. All patients were simultaneously listed for lung
transplantation while LVR was scheduled. After LVR,
patients were evaluated at 3 and 6 months after the
operation. Repeat pulmonary function studies and
6MWTs were performed. At 6 months, if the patients had
a sustained and satisfactory result (primary success) from
their LVR operation, they were then removed from the
list (placed on status 7). Those patients who had an
unsatisfactory outcome after LVR were then kept on the
lung transplant list and the LVR was considered a primary
failure. Patients placed on status 7 were continuously
evaluated by the lung transplant program for any signs of
future progressive decline in their pulmonary function
(late failure). For some of these patients, it is probable
that LVR will act to delay or postpone, but not to
eliminate, the need for lung transplantation. It should be
noted that our average time spent on the waiting list
before lung transplantation is currently approximately 18
months.
Surgical procedures. LVR was performed by a video-
assisted thoracic approach in 87% of the patients and by
a bilateral median sternotomy in 13%. Twelve patients
(39%) in this study (n 5 31) had FEV1 # 19% predicted.
It is our bias that patients with poor FEV1 have higher
perioperative mobidity and mortality.17 Therefore we try
to avoid bilateral manipulation of the lungs in this high-
risk group and use bilateral video sequential LVR as the
procedure of choice for patients with FEV1 # 19%
predicted. Seventeen patients (55%) with FEV1 $ 20%
predicted had bilateral LVR. Four of these patients had
median sternotomy, and the remaining 13 had a bilateral
video-assisted thoracic approach. The 12 patients with
FEV1 # 19% predicted were offered the bilateral sequen-
tial video-assisted thoracic approach. Five of these pa-
tients completed the second side, but the remaining seven
patients had such a satisfactory result that they either
refused or postponed completion of the contralateral
lung, confirming previous reports regarding the efficacy of
unilateral LVR.14, 15 Two patients had planned unilateral
LVR as a result of previous thoracotomy and significant
V/Q mismatch.
LVR operative technique. All patients were placed into
a supine position. Those who underwent median sternot-
omy had a standard procedure as described else-
where.13, 16 The bilateral video thoracic procedure was
performed with the patient in the supine position with a
beanbag strategically placed so that the table could roll to
30 degrees, exposing an anterolateral position on each
side. The arms were placed above the face in a flexed
position as originally described for bilateral sequential
lung transplantation.8 Epidural anesthesia was used in all
patients, as well as double-lumen endotracheal tubes.
Hypoperfused areas of lung, defined by V/Q scanning,
allowed us to target areas of lung for resection. Approx-
imately 20% of the lung tissue from each lung was
removed as wedge resections. Those patients operated on
by use of a median sternotomy also had bovine pericardial
buttressing of the pulmonary staple lines.
Statistical analysis. All means are expressed as the
mean 6 the standard deviation. Two-tailed t tests were
used to compare the means of normally distributed vari-
Table I. Patient demographics
Patient demographics (N 5 31) Mean Standard deviation
Age (yr) 53.4 6.3
% Male* 34.5 —
Preoperative FEV1 (% predicted)† 23.3 4.8
Preoperative RV (% predicted) 258.0 36.2
Preoperative 6MWT (ft) 962 326
PAS (mm Hg) 33.5 5.9
PCO2 (torr) 41.4 5.6
%IBW 109.9 21.3
V/Q scan‡
Upper left third (%) (n 5 28) 7.2 3.7
Upper right third (%) (n 5 28) 5.1 3.0
Lower left third (%) (n 5 3) 4.9 1.2
Lower right third (%) (n 5 3) 6.3 1.3
FEV1, Forced expiratory volume in 1 sec; RV, residual volume; 6MWT,
distance covered during a 6-minute walk test; PAS, pulmonary artery
systolic pressure; PCO2, partial pressure of arterial carbon dioxide; %IBW,
percent of ideal body weight.
*All variables expressed as the mean except for % Male.
†Twelve of 31 patients had FEV1 # 19% of predicted.
‡V/Q scan results were quantitated by dividing lack lung perfusion unit
into upper third, middle third, and lower third. Twenty-eight patients were
“classic” with apical “heterogeneity” on V/Q scan.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 1
Bavaria et al. 1 1
ables in independent groups. Statistical significance was
considered to be achieved where p is , 0.05.
Results
Initial (primary) results. All 31 patients with
acceptable criteria for both LVR and lung trans-
plantation were entered into the prospective algo-
rithm (Fig. 1). LVR was performed on all 31 pa-
tients, and they were evaluated at 4 to 6 months.
There were 24 primary successes (77%), and 7
primary failures (23%) (Fig. 2). Patients in the
primary success group were placed on status 7 (n 5
24), and those with primary failure were kept on the
transplant list and accrued time.
Perioperative mortality. One patient (1/31,
2.9%) died during the perioperative period. This
was a patient with A-1 disease who underwent
bilateral LVR by use of a median sternotomy. This
Fig. 1. Results/patient flow from prospective LVR/transplant algorithm. Note: three patients underwent
transplantation; two of four late failures did not meet ongoing criteria for transplant; two of six patients
with primary failure were subsequently deactivated from the list for noncompliance.
Fig. 2. Initial FEV1 response (n 5 28): primary successes versus primary failures. This graph shows the
results in FEV1 after LVR of the primary success group and primary failure group. Patients with primary
successes were then placed on status 7. Those with primary failure were kept on the transplant list. p Value
shown refers to the difference in percent change in FEV1.
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patient also had an extensive history of alcohol
abuse and had delirium tremors while in the regular
inpatient department on postoperative day 3. Adult
respiratory distress syndrome developed, with even-
tual respiratory failure. No other patient required
tracheostomy or postopertive mechanical ventila-
tion.
Functional results. Pulmonary function testing
and 6MWT results for the primary success (n 5 24)
and primary failure (n 5 7) groups are shown in
Table II.
Examination of primary failures. Two patients in
the primary failure group had A-1 disease. At 6
months’ follow-up, their pulmonary function test
results were not significantly improved. One patient,
who had a left unilateral LVR, had a V/Q scan that
showed 71% of flow to the right side and 29% of
flow to the left side. On further examination, the
patient showed evidence of a unilateral “vanishing
lung syndrome” and was probably a poor candidate
for LVR. A fourth patient had a very poor preop-
erative carbon monoxide diffusing capacity (DLCO)
Fig. 3. Intermediate-term pulmonary function decline in primary success cohort. This graph demonstrates
the decline in pulmonary function over a 12-month period in patients with a primary LVR success. Four
of 21 primary successes were subsequent late failures. Note that these four patients (late failures) had rapid
early declines in FEV1. p Value shown represents the difference in rate of decline between the continued
successes and the late failures, from the point at which peak FEV1 was reached (mean time 5 4.0 months)
until most recent testing (mean time 5 12.0 months). Two of four with late failure were put back on the
list and underwent transplantation; the remaining two (mean 5 26 months after LVR) were subsequently
considered poor candidates for transplantation because of age (both 65 years old at present), recently
acquired heart failure, and worsening osteoporosis.
Table II. Functional outcomes of initial past LVR review
Group Pre FEV1 Post FEV1 Pre RV Post RV Pre 6MWT
Post
6MWT
Primary success (n 5 24) 23% 35% 266% 205% 848 ft 1287 ft
p 5 0.0002 p 5 .00001 p 5 .00002
Primary failure (n 5 7) 26.5% 25% 228% 232% 1119 ft 1212 ft
p 5 NS p 5 NS p 5 NS
LVR, Lung volume reduction; FEV1, forced expiratory volume in 1 second; RV, residual volume; 6MWT, 6-minute walk test distance. p values shown represent
results of two-tailed t tests of paired data.
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value (7 5 25% of predicted). He had good FEV1
and RV improvement after LVR but had a signifi-
cant increase in oxygen requirements. This was even
more dramatic during exercise. For this reason, we
believed that this was an LVR failure and kept him
on the transplant list. The remaining two patients in
whom LVR was considered a primary failure had
“classic” apical disease and we can find no specific
reason for their poor initial LVR results.
Effect of strict inclusion criteria. Further analysis
of the results reveals that patients with “classic”
disease, defined as a V/Q scan showing , 10% flow
to each upper-third lung field (apical emphysema-
tous disease) and RV . 225%, did quite well. This
excludes patients with previous thoracotomy, very
low DLCO, A-1, and significant V/Q scan flow
imbalance to either lung. In patients with this strict
classification of apical emphysematous disease the
primary success rate was 94%.
Examination of late failures. Four of the 24
patients in whom LVR was a primary success
(16.7%) eventually declined to the point at which
their pulmonary function was very poor, requiring
reevaluation and relisting for transplantation. The
remaining 20 patients continue to have a clinically
satisfactory result. Eleven of these continued suc-
cesses (55%) had long-term data (mean follow-up
time of 10 months) that permitted us to compare the
slope of pulmonary function decline relative to the
four late failures. A significantly different slope of
pulmonary function decline was found between
these two groups (Fig. 3). Three patients who are
doing well after LVR do not have 6-month fol-
low-up at this time and therefore were excluded
from this longer term analysis, although at present
they are in the primary success group. The remain-
ing six have not had satisfactory objective follow-up
past 1 year. Two of these patients moved away from
the geographic area. The other four patients feel
good subjectively at this time and their results are
still considered a continued success. Two of the four
experiencing late failure were reevaluated for lung
transplantation, put on the list again, and had
successful transplantation without difficulty. The re-
maining two patients were put on the list again and
subsequently removed because of heart failure and
osteoporosis; both patients were 65 years of age at
the time.
Fig. 4. Percentage of evaluated patients with COPD subsequently listed for lung transplantation only.
Excludes both (1) patients with a standard contraindication to transplant and (2) those placed on the
“prospective” LVR management algorithm. Note: Lung transplant program evaluations initiated in July
1991.
Table III. Results for patients with initial LVR then







FEV1 (% predicted) 25.0 6 7.0 27.3 6 6.7 62.7 6 21.6
RV (% predicted) 243.3 6 39.7 179.0 6 64.2 112.5 6 58.7
LVR, Lung volume reduction; FEB1, forced expiratory volume in 1 second;
RV, residual volume. All values expressed as mean 6 standard deviation.
Mean time from date of LVR to date of lung transplant is 14.0 6 8.5
months.
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SLT. Three patients have undergone transplan-
tation as of the writing of this article after LVR. SLT
was performed without substantial added difficulty
after LVR. The functional “timeline” for these
patients is shown in Table III. Three post-LVR
patients currently remain on the transplant list
awaiting SLT.
Effect of prospective management algorithm on
transplant list composition. Fig. 4 shows the grad-
ual decrease in the percent of evaluated patients
with COPD who are directly listed. This excludes
both patients with a standard contraindication to
transplantation and those placed on the “prospec-
tive LVR management algorithm.” Fig. 5 shows the
changes in composition of the lung transplant list by
diagnosis over time. The percentage of patients with
a diagnosis of COPD on the transplant list has been
decreasing since the inception of this program, as
noted by the upper arrow on Fig. 4. In addition, the
percentage of pulmonary hypertension diagnoses on
our transplant list has decreased and idiopathic
pulmonary fibrosis, cystic fibrosis, and all other
complex diagnoses have corrrespondingly increased.
Discussion
At present, our institution has performed 155
lung transplant and 166 LVR procedures. It became
clear to us, in late 1993, that some patients would
meet the criteria for both (or either) procedures. A
strategy to properly manage these patients was
needed. We initiated a prospective management
algorithm for patients who were candidates for both
Fig. 5. Changes in composition of the lung transplant list over time. Note decreasing percentage of COPD
and pulmonary hypertension diagnoses and the increased percentages of interstitial pulmonary fibrosis,
cystic fibrosis, and other complex end-stage lung disease. The first arrow shows when LVR Prospective
Management Algorithm was initiated; the second arrow shows when in-house IV Prostacyclin Protocol
began for treatment of patients with pulmonary hypertension. NOTE: percent of patients with COPD on
the list would have been even lower if medical treatment of primary pulmonary hypertension was not so
successful. PH, Primary pulmonary hypertension and Eisenmenger’s syndromes; IPF, interstitial pulmonary
fibrosis; CF, cystic fibrosis. Complex/Other, pulmonary alveolar microlithiasis, bronchiolitis obliterans,
sarcoidosis, lymphangioleiomyomatosis, scleroderma, bronchiectasis, Noonan’s syndrome, chronic pulmo-
nary embolism, pulmonary venous obstructive disease, asthma, Kartagener’s syndrome, berylliosis, chronic
granulomatous disease, and silicosis.
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surgical treatments for emphysema and A-1
(COPD). The analysis of this pilot study focuses on
31 patients who were identified prospectively to
meet the criteria for both LVR and transplantation.
The prospective LVR/transplant management algo-
rithm consisted of 6 weeks of pulmonary rehabilitation
with simultaneous listing for transplantation. LVR was
scheduled and completed after 6 weeks of pulmonary
rehabilitation. Four to 6 months after LVR, a com-
plete evaluation was performed, including FEV1, RV,
and 6MWT tests. At that time, the treatments were
declared either a primary success or a primary failure.
Treatment of 77% of the patients was a primary
successes and treatment of 23% was considered a
primary failure. The primary failure group was kept on
the transplant list, and the primary success group was
considered status 7 and followed up by the lung
transplant team. Of the patients with initially satisfac-
tory results, 16.7% then had pulmonary function de-
cline and required reevaluation and potential relisting
for transplantation.
As reported by other authors,15, 16, 18 the mean
improvement in FEV1 was approximately 50% in
our primary success cohort. Further analysis of the
data suggests that if we are more rigorous in our
selection criteria and exclude patients with previous
thoracotomy, low DLCO, and A-1, we may be able
to improve the frequency of our primary successes.
These data would corroborate the emerging consen-
sus that patients with “classic” apical emphysema-
tous disease with high RVs and significant V/Q
heterogeneity are the best candidates for this pro-
cedure.17 Interestingly, despite our data showing
these patients with classic apical disease performing
better initially, some patients still had significant late
decline in pulmonary function.
In this pilot program, we identified a significant
percentage of patients in whom the need for trans-
plantation was delayed or even eliminated. The LVR
procedure is safe in this group of very severely
compromised patients with COPD. Of our patient
population 39% had FEV1s of # l9% of predicted,
and our overall mortality was 3.2%. On the other
hand, in 23% of the patients who entered our
prospective algorithm LVR was a primary failures,
with an additional four patients having substantial
decline and late failure. Overall, this corresponds to
32% of the entire prospective cohort potentially
requiring lung transplantation for both initial and
late LVR failure. This evidence amplifies the neces-
sity for continued surveillance of these critically ill
patients on the status 7 transplant list.
As noted by Dusmet and colleagues,19 SLT after
LVR was technically successful in three patients.
Results of lung transplantation were comparable to
previously published improvements in pulmonary
function after SLT.6, 9, 20 Two of three patients with
A-1 had poor initial results. The third patient had
relatively minor improvements in FEV1 but does
have a significant subjective improvement and is
therefore still considered to have continued success
at this time. These results suggest that patients with
A-1 disease may not be proper candidates for this
prospective management algorithm using LVR as a
means to extend eventual lung transplantation.
Other reports have also alluded to the fact that LVR
for patients with A-1 disease may not lead to
uniformly satisfactory results compared with classic
apical emphysematous disease.16, 21, 22
The availability of LVR has made an impact on
our transplant list composition and our end-stage
COPD transplant evaluation process. At present, we
list a smaller percentage of patients with COPD
than we did previously. The percentage of COPD
patients directly listed after initial evaluation
peaked in 1994. Moreover, our lung transplant list
composition has a lower percentage of patients with
COPD compared with previous years. The reasons
for this are complex and may have to do with a
combination of multiple factors: (1) the initiation of
LVR, (2) the addition of an outpatient intravenous
prostacyclin protocol for pulmonary hypertension,
(3) the fact that our lung transplant program has
become more experienced since its inception in July
1991, and (4) the percentage of complex cases and
referrals such as cystic fibrosis, sarcoidosis, and
interstitial pulmonary fibrosis have increased.
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Discussion
Dr. G. Alexander Patterson (St. Louis, Mo.). Dr. Ba-
varia and his colleagues have brought to our attention a
very important problem in the evaluation of emphysema
patients for surgical management.
At first glance, it may seem that a selection dilemma
exists between LVR and transplantation for patients with
advanced end-stage emphysema. In fact, there really are
very few patients for whom either option is suitable;
indeed, in the Pennsylvania experience, only 31 of 225
evaluated patients were thought suitable for either proce-
dure. These patients were listed for transplant before
LVR. That is a sensible option given the expected 18
months’ pretransplant waiting time in their program.
Although three quarters of these patients did derive
benefit from LVR and may be considered to have been
bridged to future transplantation, a quarter of the patients
derived no benefit. One early death occurred, and survi-
vors actually had worse pulmonary function after the
procedure than before it. These patients were not bridged
to transplantation, certainly. In fact, realizing the low
mortality for emphysema on transplant waiting lists, I
would suggest that these patients who derived no benefit
from LVR would have been better served by transplant as
the initial procedure. Therefore the problem as usual
comes down to patient selection.
Dr. Bavaria, can you identify specific parameters in
these patients in whom LVR failed, which would now lead
to you recommend primary transplantation rather than
LVR?
I would also be interested to know whether the tech-
nique of LVR predicts a poor outcome in certain of these
patients?
In our program we have adopted a slightly different
attitude in terms of selection for patients who are approach-
ing 65 years of age. Taking into account a lengthy waiting
time for a donor, we generally consider that they are going to
get one operation and try and make the best judgment we
can as to whether it should be transplant or LVR.
We have not noticed a significant change in the number
of emphysema patients on our waiting list or the number
of emphysema patients that we are evaluating. I think that
the change in your list may reflect the fact that other
transplant programs are now up and running in your
region. In addition, I am sure that your transplant expe-
rience, the cases you do and evaluate, has also changed as
your program gained experience.
Dr. Mark J. Krasna (Baltimore, Md.). Have you noticed
any increase in either morbidity or mortality in perform-
ing the transplant after the bilateral LVR whether by
thoracostomy or sternotomy as opposed to the patient
population that had no previous pulmonary operations
undergoing a standard transplant for COPD?
Dr. Bavaria. I want to answer that question first. It is a
little more technically difficult, but we did not have any
differences in the extubation times or the results com-
pared with regular SLT for COPD. We were, actually,
pleasantly surprised by the fact that the technical lung
transplant after LVR—and we do most of our LVRs with
a pleurodesis at the same time—was not quite as difficult
as I thought.
Dr. Patterson’s questions are appropriate. I think we do
have multiple factors regarding the composition of our
lung transplant list and how it has become more complex,
and I think those do include the fact that our center is
probably the most mature center in this area and we do
have patients with more complications. Also, the major
decrease in pulmonary hypertension cases in most lung
transplant lists has a major effect on the lung transplant
composition compared with before.
Regarding the technical questions that Dr. Patterson
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alluded to, no difference exists between the video-thoracic
and the median sternotomy approaches in our experience
looking at the 180 LVRs that we have done. I do, however,
believe that we use the scope to operate on our patients
with A-1 disease, and maybe that might have not been the
right method.
To address the other question you asked about selec-
tion, I believe we will get better results with LVR if we
stick, especially in these low FEV1 patients, to classic
disease. I do not think patients with A-1 disease did well
in our group nor did patients with atypical V/Q scan
changes. But if you stick with the apical disease, classic
disease with low flows to each of the upper apical thirds,
they did pretty well.
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